REXAHN PHARMACEUTICALS INC's ticker is RNN and the CUSIP is 761640101. A total of 21 filers reported holding REXAHN PHARMACEUTICALS INC in Q2 2013. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2017 | $42,000 | +320.0% | 82,391 | +20.3% | 0.00% | – |
Q4 2016 | $10,000 | -28.6% | 68,500 | 0.0% | 0.00% | – |
Q3 2016 | $14,000 | -17.6% | 68,500 | -1.2% | 0.00% | – |
Q2 2016 | $17,000 | -26.1% | 69,312 | 0.0% | 0.00% | – |
Q1 2016 | $23,000 | +91.7% | 69,312 | +118.3% | 0.00% | – |
Q4 2015 | $12,000 | -29.4% | 31,748 | 0.0% | 0.00% | – |
Q3 2015 | $17,000 | 0.0% | 31,748 | +14.3% | 0.00% | – |
Q2 2015 | $17,000 | -15.0% | 27,783 | 0.0% | 0.00% | – |
Q1 2015 | $20,000 | +5.3% | 27,783 | +0.5% | 0.00% | – |
Q4 2014 | $19,000 | +18.8% | 27,658 | +39.3% | 0.00% | – |
Q3 2014 | $16,000 | -72.4% | 19,860 | -70.0% | 0.00% | – |
Q2 2014 | $58,000 | -26.6% | 66,123 | -9.1% | 0.00% | – |
Q1 2014 | $79,000 | +276.2% | 72,733 | +74.2% | 0.00% | – |
Q4 2013 | $21,000 | +16.7% | 41,755 | +6.3% | 0.00% | – |
Q3 2013 | $18,000 | +5.9% | 39,286 | 0.0% | 0.00% | – |
Q2 2013 | $17,000 | – | 39,286 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Anson Funds Management LP | 18,340,000 | $3,852,000 | 0.41% |
SABBY MANAGEMENT, LLC | 9,464,849 | $1,988,000 | 0.07% |
Northeast Financial Consultants Inc | 150,000 | $31,000 | 0.01% |
HUDSON VALLEY INVESTMENT ADVISORS INC /ADV | 200,000 | $42,000 | 0.01% |
TWO SIGMA SECURITIES, LLC | 185,239 | $39,000 | 0.01% |
Benin Management CORP | 93,000 | $20,000 | 0.01% |
CONDOR CAPITAL MANAGEMENT | 145,000 | $30,000 | 0.01% |
NIXON PEABODY TRUST CO | 10,000 | $2,000 | 0.00% |
Tower Research Capital LLC (TRC) | 47,677 | $10,000 | 0.00% |
Renaissance Technologies | 3,201,993 | $672,000 | 0.00% |